E-slide Library

Initiating and selecting biologic therapy for IBD: A faculty roundtable discussion


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Disease
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA


Miguel D. Regueiro, MD
Professor of Medicine
Associate Chief for Education
Co-Director, Inflammatory Bowel Disease Center
University of Pittsburgh
Pittsburgh, PA


Bruce E. Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY



The mainstay biologic therapy for IBD is anti-TNF therapy, based on clinical trial data, long-term follow-up data, and personal patient and physician experience. However, with the approval in 2014 of vedolizumab for ulcerative colitis (UC) and Crohn's disease (CD), the treatment algorithm has become more complex. Using a roundtable format, this IBD Dialog will provide expert-led discussion on when to consider a biologic therapy, and "tips and pointers" for the selection of therapy (anti-TNF vs anti-integrin).

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release date: August 19, 2015

Learning objectives

After completing this activity, the participant should be better able to:

  • Discuss factors to consider when initiating a first biologic in CD and UC
  • Evaluate the different biologics available for first line therapy
  • Summarize the principles for monotherapy vs combination therapy in IBD
  • Provide appropriate care and counsel for patients and their families.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

View Presentation